Drug Trial Radar · NCT02559778
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Sep 2015
Primary completion
Sep 2030
Study completion Sep 2035
Sponsor
- Lead sponsor
- Giselle ShollerAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Dell, Inc.; Beat NB Cancer Foundation; K C Pharmaceuticals Inc.; Team Parker for Life
- First posted
- Sep 24, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Newly Diagnosed High-Risk Neuroblastoma.
Conditions
- Neuroblastoma
Interventions
CeritinibDrug
One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
dasatinibDrug
One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
sorafenibDrug
One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
vorinostatDrug
One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
DFMODrug
DFMO will be given to Arm B during immunotherapy and then for 2 years as maintenance to all subjects completing immunotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of days from start of therapy to date of first relapseTime frame: Up to 8 years
- Number of subjects that have a targeted agent chosen for treatment.Time frame: 2 years
- Number of subjects that receive 75% of dosing of medications while on study protocol during cycles 3-6.Time frame: 2 years
Locations
28 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama/Children's of Alabama
Birmingham, Alabama · Recruiting
Arkansas Children's Hospital
Little Rock, Arkansas · Recruiting
UCSF Benioff Children's Hospital Oakland
Oakland, California · Recruiting
Rady Children's Hospital
San Diego, California · Recruiting
Connecticut Children's Hospital
Hartford, Connecticut · Recruiting
Nicklaus Children's Miami
Miami, Florida · Recruiting
Arnold Palmer Hospital for Children
Orlando, Florida · Recruiting
St. Joseph's Children's Hospital
Tampa, Florida · Recruiting
Augusta University Health
Augusta, Georgia · Recruiting
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii · Recruiting
St. Lukes
Boise, Idaho · Completed
Advocate Aurora Research Institute
Chicago, Illinois · Completed
Norton Children's Research Institute/Affiliated with University of Louisville School of Medicine
Louisville, Kentucky · Recruiting
Helen DeVos Children's Hospital
Grand Rapids, Michigan · Recruiting
Children's Hospital and Clinics of Minnesota
Minneapolis, Minnesota · Recruiting
Children's Mercy Hospitals and Clinics
Kansas City, Missouri · Completed
Cardinal Glennon Children's Medical Center
St Louis, Missouri · Recruiting
Hackensack University Medical Center
Hackensack, New Jersey · Completed
Levine Children's Hospital
Charlotte, North Carolina · Recruiting
Randall Children's Hospital
Portland, Oregon · Recruiting
Penn State Milton S. Hershey Medical Center and Children's Hospital
Hershey, Pennsylvania · Recruiting
Medical University of South Carolina
Charleston, South Carolina · Recruiting
Dell Children's Blood and Cancer Center
Austin, Texas · Recruiting
Children's Medical Center
Dallas, Texas · Recruiting
Alberta Children's Hospital
Calgary, Alberta, Canada · Recruiting
CHU Sainte-Justine
Montreal, Quebec, Canada · Recruiting
CHUQ
Québec, Quebec, Canada · Recruiting
CIUSSS de l'Estrie-CHUS
Sherbrooke, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.